Oftaquix (Levofloxacin Hemihydrate)

Levofloxacin blocks bacterial DNA gyrase and topoisomerase IV, enzymes that are essential for DNA replication and transcription. This inhibition stops bacterial cell division and leads to bacterial death, providing a bactericidal effect against susceptible organisms.

The dosage of Oftaquix is individualized by the prescribing clinician based on the type and severity of infection, patient age, weight, renal function and other clinical factors. The prescriber determines the appropriate strength, frequency and duration of therapy.

Levofloxacin is classified as pregnancy category C in many regions, indicating that it should only be used when the potential benefit justifies the potential risk to the fetus. It is excreted in breast milk, so breastfeeding mothers should discuss risks and alternatives with their healthcare provider.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Levofloxacin offers a once‑daily dosing schedule and broad‑spectrum activity against both Gram‑negative and Gram‑positive bacteria, which can be an advantage over some older fluoroquinolones that require multiple daily doses. Its spectrum and pharmacokinetic profile differ from macrolides or β‑lactams, making it a useful alternative when those agents are unsuitable or resistance is a concern.

Oftaquix should be stored at temperatures below 25 °C, in its original packaging, protected from moisture and direct sunlight. Maintaining these conditions helps preserve the tablet’s stability and potency throughout its shelf life.

Oftaquix is supplied as an oral tablet that is taken by mouth with or without food, as directed by the prescribing clinician. The tablet should be swallowed whole with an adequate amount of water and not chewed or crushed unless specifically instructed.

Serious adverse events linked to levofloxacin include tendon rupture, QT‑interval prolongation leading to cardiac arrhythmias, severe allergic reactions, peripheral neuropathy and Clostridioides difficile‑associated colitis. Patients should be advised to seek immediate medical attention if they experience sudden tendon pain, palpitations, rash or persistent diarrhea.

Levofloxacin is contraindicated in individuals with a known hypersensitivity to fluoroquinolones, those with a history of tendon disorders related to fluoroquinolone therapy, and patients with certain cardiac conditions that predispose them to QT prolongation. It should also be used with caution in pregnant or lactating women and in patients with severe renal impairment.